Editas Medicine (EDIT) Non Operating Income (2015 - 2025)
Editas Medicine (EDIT) reported Non Operating Income of -$569000.0 for Q3 2025, down 11280.0% year-over-year from N/an in Q3 2024, and up 67.63% on a QoQ basis from -$1.8 million in Q2 2025.
Editas Medicine (EDIT) has 11 years of Non Operating Income data on file, last reported at -$569000.0 in Q3 2025.
- Quarterly Non Operating Income fell 11280.0% year-over-year to -$569000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $11.3 million (up 164.0% YoY) and the FY2024 annual result came in at $14.1 million, up 976.5% from the prior year.
- Non Operating Income advanced to -$569000.0 in Q3 2025 per EDIT's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Non Operating Income topped out at $14.1 million in Q4 2024 and bottomed at -$1.8 million in Q2 2025.
- The 5-year median for Non Operating Income is $6000.0 (2024), against an average of $1.4 million.
- The widest annual swing landed in 2023, when Non Operating Income surged 514300.0%; it then tumbled 11280.0% in 2025.
- Tracing EDIT's Non Operating Income over 5 years: stood at -$433000.0 in 2021, then jumped by 99.08% to -$4000.0 in 2022, then plunged by 250.0% to -$14000.0 in 2023, then jumped by 100521.43% to $14.1 million in 2024, then plunged by 104.05% to -$569000.0 in 2025.
- Per Business Quant, the three latest EDIT Non Operating Income figures stand at -$569000.0 (Q3 2025), -$1.8 million (Q2 2025), and -$425000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -569,000.00 |
| Jun 30, 2025 | -1.76 Mn |
| Mar 31, 2025 | -425,000.00 |
| Dec 31, 2024 | 14.06 Mn |
| Sep 30, 2024 | -5,000.00 |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | -14,000.00 |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 3.80 Mn |
| Mar 31, 2023 | 1.93 Mn |
| Dec 31, 2022 | -4,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 781,000.00 |
| Mar 31, 2022 | -234,000.00 |
| Dec 31, 2021 | -433,000.00 |
| Sep 30, 2021 | 171,000.00 |
| Jun 30, 2021 | 145,000.00 |
| Mar 31, 2021 | 155,000.00 |
| Dec 31, 2020 | 3.38 Mn |
| Sep 30, 2020 | -1.17 Mn |
| Jun 30, 2020 | 7.18 Mn |
| Mar 31, 2020 | 8.89 Mn |
| Dec 31, 2019 | 1.65 Mn |
| Sep 30, 2019 | 1.65 Mn |
| Jun 30, 2019 | 1.86 Mn |
| Mar 31, 2019 | 2.01 Mn |
| Dec 31, 2018 | 1.20 Mn |
| Sep 30, 2018 | 1.02 Mn |
| Jun 30, 2018 | 934,000.00 |
| Mar 31, 2018 | 620,000.00 |
| Dec 31, 2017 | 253,000.00 |
| Sep 30, 2017 | 150,000.00 |
| Jun 30, 2017 | -324,000.00 |
| Mar 31, 2017 | -470,000.00 |
| Dec 31, 2016 | -392,000.00 |
| Sep 30, 2016 | 145,000.00 |
| Jun 30, 2016 | 158,000.00 |
| Mar 31, 2016 | 94,000.00 |
| Dec 31, 2015 | -260,000.00 |
| Sep 30, 2015 | -23,000.00 |
| Jun 30, 2015 | -37.18 Mn |
| Mar 31, 2015 | -130,000.00 |